Green synthesis of MnO2 NPs using Arabic gum: assessing its potential antiviral activity against influenza A/H1N1
The antiviral properties of metal nanoparticles against various viruses, including those resistant to drugs, are currently a subject of intensive research. Recently, the green synthesis of nanoparticles and th... (Source: Virology Journal)
Source: Virology Journal - February 23, 2024 Category: Virology Authors: Neda Baghban, Safieh Momeni, Emad Behboudi, Hassan Dianat-Moghadam, Amirhossein Darabi, Hadiseh Shokouhi Targhi and Mohsen Keshavarz Tags: Brief Report Source Type: research
Measuring waning protection from seasonal influenza vaccination during nine influenza seasons, Ontario, Canada, 2010/11 to 2018/19
ConclusionsInfluenza vaccine protection wanes during an influenza season. Understanding the optimal timing of vaccination could ensure robust protection during seasonal influenza activity. (Source: Eurosurveillance)
Source: Eurosurveillance - February 22, 2024 Category: Infectious Diseases Authors: Hannah Chung, Michael A Campitelli, Sarah A Buchan, Aaron Campigotto, Natasha S Crowcroft, Jonathan B Gubbay, James KH Jung, Timothy Karnauchow, Kevin Katz, Allison J McGeer, J Dayre McNally, David C Richardson, Susan E Richardson, Laura C Rosella, Margar Source Type: research
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: −3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: ͨ...
Source: Eurosurveillance - February 22, 2024 Category: Infectious Diseases Authors: Marine Maurel, Jennifer Howard, Esther Kissling, Francisco Pozo, Gloria P érez-Gimeno, Silke Buda, Noémie Sève, Adele McKenna, Adam Meijer, Ana Paula Rodrigues, Iván Martínez-Baz, Ivan Mlinarić, Neus Latorre-Margalef, Gergő Túri, Mihaela Lazăr, C Source Type: research
2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)
Euro Surveill. 2024 Feb;29(7). doi: 10.2807/1560-7917.ES.2024.29.7.2400076.ABSTRACTThe Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51-72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33-71) than clade 5a.2a (67%; 95% CI: 48-80), and lowest against influenza A(H3N2) (40%; 95% CI: 5-61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI: 21-65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95% CI: 28-85).PMID:38362622 |...
Source: Euro Surveill - February 16, 2024 Category: Infectious Diseases Authors: Danuta M Skowronski Yuping Zhan Samantha E Kaweski Suzana Sabaiduc Ayisha Khalid Romy Olsha Sara Carazo James A Dickinson Richard G Mather Hugues Charest Agatha N Jassem In ès Levade Maan Hasso Nathan Zelyas Ruimin Gao Nathalie Bastien Source Type: research
Progress of Influenza Viruses and Inhibitors
Curr Med Chem. 2024 Feb 15. doi: 10.2174/0109298673268314231204061224. Online ahead of print.ABSTRACTInfluenza is an acute respiratory disease caused by influenza viruses. It has the characteristics of fast transmission and strong infectivity, and it does great harm to human health and survival. It is estimated that the seasonal influenza epidemics every year will cause about one billion cases of infections and hundreds of thousands of deaths worldwide, while influenza A virus is the leading cause of infection and death. Currently, the main drugs used in clinics to treat influenza viruses are neuraminidase inhibitors, and ...
Source: Current Medicinal Chemistry - February 16, 2024 Category: Chemistry Authors: Yuchen Xiao Jianping Yong Shaoji Lu Canzhong Lu Ruiwen Huang Source Type: research
2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)
Euro Surveill. 2024 Feb;29(7). doi: 10.2807/1560-7917.ES.2024.29.7.2400076.ABSTRACTThe Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51-72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33-71) than clade 5a.2a (67%; 95% CI: 48-80), and lowest against influenza A(H3N2) (40%; 95% CI: 5-61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI: 21-65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95% CI: 28-85).PMID:38362622 |...
Source: Euro Surveill - February 16, 2024 Category: Infectious Diseases Authors: Danuta M Skowronski Yuping Zhan Samantha E Kaweski Suzana Sabaiduc Ayisha Khalid Romy Olsha Sara Carazo James A Dickinson Richard G Mather Hugues Charest Agatha N Jassem In ès Levade Maan Hasso Nathan Zelyas Ruimin Gao Nathalie Bastien Source Type: research
Progress of Influenza Viruses and Inhibitors
Curr Med Chem. 2024 Feb 15. doi: 10.2174/0109298673268314231204061224. Online ahead of print.ABSTRACTInfluenza is an acute respiratory disease caused by influenza viruses. It has the characteristics of fast transmission and strong infectivity, and it does great harm to human health and survival. It is estimated that the seasonal influenza epidemics every year will cause about one billion cases of infections and hundreds of thousands of deaths worldwide, while influenza A virus is the leading cause of infection and death. Currently, the main drugs used in clinics to treat influenza viruses are neuraminidase inhibitors, and ...
Source: Current Medicinal Chemistry - February 16, 2024 Category: Chemistry Authors: Yuchen Xiao Jianping Yong Shaoji Lu Canzhong Lu Ruiwen Huang Source Type: research
2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)
Euro Surveill. 2024 Feb;29(7). doi: 10.2807/1560-7917.ES.2024.29.7.2400076.ABSTRACTThe Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51-72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33-71) than clade 5a.2a (67%; 95% CI: 48-80), and lowest against influenza A(H3N2) (40%; 95% CI: 5-61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI: 21-65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95% CI: 28-85).PMID:38362622 |...
Source: Euro Surveill - February 16, 2024 Category: Infectious Diseases Authors: Danuta M Skowronski Yuping Zhan Samantha E Kaweski Suzana Sabaiduc Ayisha Khalid Romy Olsha Sara Carazo James A Dickinson Richard G Mather Hugues Charest Agatha N Jassem In ès Levade Maan Hasso Nathan Zelyas Ruimin Gao Nathalie Bastien Source Type: research
2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)
Euro Surveill. 2024 Feb;29(7). doi: 10.2807/1560-7917.ES.2024.29.7.2400076.ABSTRACTThe Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51-72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33-71) than clade 5a.2a (67%; 95% CI: 48-80), and lowest against influenza A(H3N2) (40%; 95% CI: 5-61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI: 21-65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95% CI: 28-85).PMID:38362622 |...
Source: Euro Surveill - February 16, 2024 Category: Infectious Diseases Authors: Danuta M Skowronski Yuping Zhan Samantha E Kaweski Suzana Sabaiduc Ayisha Khalid Romy Olsha Sara Carazo James A Dickinson Richard G Mather Hugues Charest Agatha N Jassem In ès Levade Maan Hasso Nathan Zelyas Ruimin Gao Nathalie Bastien Source Type: research
2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)
Euro Surveill. 2024 Feb;29(7). doi: 10.2807/1560-7917.ES.2024.29.7.2400076.ABSTRACTThe Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51-72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33-71) than clade 5a.2a (67%; 95% CI: 48-80), and lowest against influenza A(H3N2) (40%; 95% CI: 5-61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI: 21-65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95% CI: 28-85).PMID:38362622 |...
Source: Euro Surveill - February 16, 2024 Category: Infectious Diseases Authors: Danuta M Skowronski Yuping Zhan Samantha E Kaweski Suzana Sabaiduc Ayisha Khalid Romy Olsha Sara Carazo James A Dickinson Richard G Mather Hugues Charest Agatha N Jassem In ès Levade Maan Hasso Nathan Zelyas Ruimin Gao Nathalie Bastien Source Type: research
2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)
Euro Surveill. 2024 Feb;29(7). doi: 10.2807/1560-7917.ES.2024.29.7.2400076.ABSTRACTThe Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51-72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33-71) than clade 5a.2a (67%; 95% CI: 48-80), and lowest against influenza A(H3N2) (40%; 95% CI: 5-61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI: 21-65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95% CI: 28-85).PMID:38362622 |...
Source: Euro Surveill - February 16, 2024 Category: Infectious Diseases Authors: Danuta M Skowronski Yuping Zhan Samantha E Kaweski Suzana Sabaiduc Ayisha Khalid Romy Olsha Sara Carazo James A Dickinson Richard G Mather Hugues Charest Agatha N Jassem In ès Levade Maan Hasso Nathan Zelyas Ruimin Gao Nathalie Bastien Source Type: research
U.S. COVID-19 vaccine distribution strategies, systems, performance, and lessons learned, December 2020 - May 2023
This article describes the infrastructure supporting the distribution of U.S. government-purchased COVID-19 vaccines that was in place pre-pandemic, and the infrastructure, processes, and communications efforts developed to support the heightened demands of the COVID-19 vaccination program, and describes lessons learned.PMID:38360476 | DOI:10.1016/j.vaccine.2024.02.020 (Source: Vaccine)
Source: Vaccine - February 15, 2024 Category: Allergy & Immunology Authors: Christopher Duggar Jeanne M Santoli Cameron Noblit Lori B Moore Roua El Kalach Carolyn B Bridges Source Type: research
U.S. COVID-19 vaccine distribution strategies, systems, performance, and lessons learned, December 2020 - May 2023
This article describes the infrastructure supporting the distribution of U.S. government-purchased COVID-19 vaccines that was in place pre-pandemic, and the infrastructure, processes, and communications efforts developed to support the heightened demands of the COVID-19 vaccination program, and describes lessons learned.PMID:38360476 | DOI:10.1016/j.vaccine.2024.02.020 (Source: Vaccine)
Source: Vaccine - February 15, 2024 Category: Allergy & Immunology Authors: Christopher Duggar Jeanne M Santoli Cameron Noblit Lori B Moore Roua El Kalach Carolyn B Bridges Source Type: research
GSE255604 Mannose remodels glucose metabolism to antagonize the overwhelming host inflammatory response
Contributors : Ronghui Liang ; Shuofeng YuanSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapienswe performed transcriptomic analysis in A549 cells and demonstrated a reduced proinflammatory response but increased host tolerance upon H1N1 virus infection and mannose therapy, providing further evidence for the beneficial role of mannose in immunometabolism. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - February 15, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)
The Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51–72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33–71) than clade 5a.2a (67%; 95% CI: 48–80), and lowest against influenza A(H3N2) (40%; 95% CI: 5–61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI: 21–65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95% CI: 28–85). (Source: Eurosurveillance)
Source: Eurosurveillance - February 15, 2024 Category: Infectious Diseases Authors: Danuta M Skowronski, Yuping Zhan, Samantha E Kaweski, Suzana Sabaiduc, Ayisha Khalid, Romy Olsha, Sara Carazo, James A Dickinson, Richard G Mather, Hugues Charest, Agatha N Jassem, In ès Levade, Maan Hasso, Nathan Zelyas, Ruimin Gao and Nathalie Bastien Source Type: research
